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Phagocyte Chemotaxis 
W. RAY GAMMON, M.D. 
The inflammatory response depends on the co-ordinated 
interaction of humoral factors and cells, particularly phagocytes 
which must leave the circulation, migrate to a site of injury or 
invasion by micro-organisms and there either phagocytose for-
eign material or release their lysosomal enzymes for digestion 
of tissue!! and foreign substances. 
Migration from the circulation to the focus of injury requires 
activation of phagocytes presumably by soluble humoral sub-
stances emanating from the site of injury. Activated phagocytes 
become "sticky," adhere to the capillary wall and migrate into 
the tissue_ Movement to the injured site then occurs in a 
directed fashion. The cells approach the site and collect not by 
a passive mechanism but by an active cell function. 
Chemotaxis (syn. cytotaxis) , is the directed migration of a 
cell toward a concentration gradient of a chemotactic factor 
(syn_ chemotaxin, chemoattractant, cytotaxin). The process 
includes 3 major components, a cell capable of directed migra-
tion, a stimulus (chemotactic factor) and a signal mechanism 
whereby the chemotactic factor activates directed movement. 
THE CELLULAR MECHANISMS OF DIRECTED 
MOTION 
Phagocyte movement, whether random or directed, requires 
adherence to a substrate, formation of pseudopods of cell mem-
brane called lamellipodia and a poorly understood process 
called cytoplasmic flow. The direction of cytoplasmic flow 
rather than the direction of pseudopod formation determines 
the course of cell movement [1]. Adherence to a solid surface 
results from a charge interaction between the cell and the 
surface. Many biological surfaces such as blood vessels are 
negatively charged. The phagocyte membrane is also negatively 
charged, but forces that repel the cell may be minimized by a 
reduction of cell membrane charge to a less negative state. 
Cheznotactic factors cause a rapid neutralization of phagocyte 
surface charge and drugs which block this effect block chemo-
taxis [2]. 
The formation of lamellipodia and flow of cytoplasm are 
controlled by the cytoskeletal system which is composed of 2 
types of contractile proteins, microtubules and microftlaments. 
Both function cooperatively in cell movement. MicrofIlaments 
are polymers of actin and myosin and provide the propulsive 
forces to move membrane and cytoplasm. Microtubules, com-
posed of a protein called tubulin, influence the direction of 
movement by a poorly understood process of asymmetric po-
lyznerization and depolymerization. Changes in tubulin polym-
erization influence the orientation of cytoplasm and presumably 
the direction cytoplasm takes when acted upon by the propul-
sive forces generated by microfilaments. Though microtubule 
function seems essential for directed migration, it is less impor-
tant in random movement [3,4]. 
Chemotactic factors may influence cells to move in a specific 
direction by an indirect effect on tubulin mediated by changes 
in the cytoplasmic level of calcium ions. When chemotactic 
factors interact with the cell membrane, calcium moves from 
the intracellular to the extracellular space [5]. Lowering of the 
intracellular calcium concentration favors the polymerization 
of tubulin. If the effect, as some investigators suspect, is greatest 
in the portion of the cell in contact with the highest concentra-
tion of chemotactic factor, the result might be a polarization of 
tubulin polyme.rization resulting in the flow of cytoplasm to-
ward the source of chemotactic factor. 
Evidence that microtubules are essential for directed move-
ment comes from several sources. It is well established that 
drugs which inhibit tubulin aggregation, antitubulins, inhibit 
directed migration without significantly affecting random mo-
tion [6]. Furthermore, patients with defective microtubular 
assembly as seen in the Chediak-Higashi syndrome (CHS) have 
faulty directed migration of their phagocytes, but relatively 
normal random migration. 
Evidence supporting a role for microfilaments in cell move-
ment comes from studies using an inhibitor of microfilament 
function, cytochalasin B [9] and from a patient with defective 
cell movement associated with abnormal polymerization of 
neutrophil actin [10]. 
THE INTERACTION OF CHEMOTACTIC FACTORS 
WITH PHAGOCYTES 
The response of phagocytes to chemotactic factors is influ-
enced by changes in cell surface enzymes, cyclic nucleotide 
levels, ion transport mechanisms and energy-producing path-
ways. These changes and how they contribute to cell movement 
help us understand the basic physiology of chemotaxis. 
Chemoattractants probably initiate cell responses by inter-
acting fIrst at the cell membrane. Initial ihteraction at this site 
is inferred from the rapidity of the cellular response to chemo-
taxins, the fact that many chemotaxins are too large to pass 
easily through the membrane and from recent evidence that 
membrane receptors exist for at. least some synthetic chemoat-
tractants. 
To date, membrane receptors have been demonstrated only 
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for the synthetic chemotactins, N-formyl di- and tri-peptides 
[11,12). None of the biologically derived factors interact com-
petitively suggesting that either there are other receptors with 
different specificities or chemotactic factors may stimulate cells 
without binding to a specific surface molecule. Several factors 
including kallikrein and plasminogen activator are chemotactic 
but only if their enzymatic functions are intact [13). 
Two serine esterases in the neutrophil have been identified 
as necessary in the mediation of the chemotactic stimulus 
[14). One of these, pro esterase I, is present in an inactive form 
until chemotactic stimulation. After stimulation, the proenzyme 
is converted to esterase I. A second esterase is present in an 
activated form prior to exposure to chemotactic factor. This 
enzyme, unlike the proenzyme, can be inhibited before chemo-
tactic factors interact with the cell. Inhibition of either esterase 
blocks the chemotactic response but it remains unknown how 
these enzymes function to relay the chemotactic signal. 
A role for membrane bound ATPase-dependent active trans-
port systems is suggested by studies showing that ATPase 
inhibitors are able to block the chemotactic response [15]. 
Transport systems are required for electrolyte transfer across 
the cell membrane and probably play a role in the shift of 
calcium and other ions necessary for cell motion. The shift of 
calcium ions, as previously noted, appears necessary for optimal 
microtubular aggregation and may be required for microfJla-
ment contraction as well. It has been postulated that the efflux 
of calcium to an extracellqlar location may be responsible for 
the neutralization of the cell surface charge required for adher-
ence [2). 
Considerable circumstantial evidence suggests an important 
role for the cyclic nucleotides, cyclic adenosine monophosphate 
(cAMP) and guanosine monophosphate (cGMP) in regulating 
the cellular response to chemotactic factors [16,17]. In general, 
an increase in the intracellular levels of cAMP or a decrease in 
cGMP causes a decrease in responsiveness. Conversely, a de-
crease in cAMP and increase in cGMP causes an increased 
response. Increased cGMP and decreased cAMP are known to 
favor tubulin aggregation and is a possible mechanism whereby 
cyclic nucleotides influence directed migration [18]. 
Changes in the levels of cyclic nucleotides are linked to 
stimulation of surface receptors on phagocytes and may offer a 
mechanism for humoral control over the chemotactic response. 
Beta adrenergic drugs such as isoproterenol and epinephrine 
increase intracellular levels of cAMP and have been reported 
to inhibit chemotaxis. Cholinergic agents acting on different 
receptors increase cGMP and increase chemotactic responsive-
ness. Histamine may inhibit neutrophil chemotaxis by stimu-
lating the H2 receptor' and increasing intracellular cAMP [19). 
A clinical example of the importance of cyclic nucleotides in 
chemotaxis is supplied by patients with CHS. They have neu-
trophil cAMP levels 8 times normal. It has been postulated that 
such elevated levels may be associated with faulty tubulin 
aggregation, which might explain not only the presence of giant 
lysosomal granules but the defective chemotaxis of CHS phag-
ocytes. In vivo and in vitro treatment of CHS phagocytes with 
ascorbic acid, a compound known to decrease cAMP and in-
crease cGMP results in substantial improvement in chemotaxis 
[20). 
Chemotaxis is an energy-dependent cell function. Chemotac-
tic stimulation of neutrophils produces a rapid increase in both 
aerobic glycolysis and hexose monophophate shunt activity 
[21]. These pathways presumably furnish sufficient high energy 
phosphates for the metabolic requirement of chemotaxis. 
How the above factors are integrated to produce directed 
motion has not been worked out, but one can speculate what 
may happen when a phagocyte comes in contact with a che-
motactic gradient. There is an initial reaction between che-
moattractant and cell membrane receptors or esterases which 
may then activate the hexose monophosphate shunt and aero-
bic glycolytic pathways for the production of ATP. The high 
energy phosphates are the energy source for membrane-asso-
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cia ted ion transport mechanisms, for microftlament contraction, 
and possibly microtubular assembly. Activated ion transport 
mechanisms facilitate the transfer of divalent actions such as 
Ca++ to extracellular sites favoring cell adherence, microftla-
ment contraction and the aggregation of tubulin . An increase in 
cGMP and a decrease in cAMP promote tubulin aggregation. 
Directed motion appears to result from the intergration of these 
and perhaps other undefined processes. 
PHAGOCYTE CHEMOT ACnC FACTORS, ORIGIN AND 
MECHANISMS OF GENERATION 
A growing number of chemotactic factors and substances 
capable of generating chemo-attractants are present in mam-
malian tissues and microorganisms. The structures, chemical 
and biological properties and tissues of origin vary greatly. 
Little information is available on the relative importance of 
specific factors in different types of inflammation. It is probable 
that in any inflammed tissue, multiple factors of varying po-
tency are active and different factors are important at various 
stages of inflammation. 
The "endogenous" chemo-attractants which originate from 
host tissues include the complement-derived proteins, C3a, C5a 
and C567 complex substances from the kinin-generating and 
coagulation-fibrinolytic pathways, kallikrein, plasminogen ac-
tivator and fibrin-split products; factors generated from the 
proteolytic dewadation of collagen and immunoglobulins and 
soluble substances. released from granulocytes and activated 
lymphocytes. 
The complement derived factors are especially important due 
to their potency and the variety of pathways that lead to their 
formation [22). Supporting a major in vivo role for these factors 
are studies which show depressed neutrophil chemotaxis in 
animals and man deficient in key complement components [23-
25], and animals artificially depleted of complement [24]; and 
reports of isolation of chemotactically-active complement fac-
tors from inflammed tissues [26,27). 
C5a is the most active of the complement factors [28). C5a 
can be generated by several mechanisms including the classical 
and alternative complement pathways and by a mechanism of 
direct activation that requires neither pathway. The latter 
mechanism is due to the activity of C5 cleaving proteases [29], 
called chemotaxigens. These enzymes have been definitely dem-
onstrated in leukocytes, platelets, myocardium and human ep-
idermis [30, 31] but may be present in all tissues. Micro-orga-
nisms too may produce C5-cleaving enzymes. Chemotaxigens 
may be very important in complement-associated inflammatory 
reactions where classical or alternative pathways of comple-
ment activation are not readily demonstrable. Activation of the 
kinin-generating and coagulation-fibrinolytic pathways are fre-
quent if not invariable accompaniments of inflammation and 
may be another important source of chemotactic factors. Many 
stimuli including crystals (pyrophosphate, uric acid), endotoxin, 
basement membranes, and exposed native collagen activate 
Hagemen factor (clotting factor #12). Activated Hagemen fac-
tor subsequently converts pre kallikrein to kallikrein and plas-
minogen proactivator to plasminogen activator. Both conver-
sion products are chemotactic in vitro [32]. 
Leukocytes produce chemotactic factors which may serve to 
augment inflammatory responses. Mast cells release a neutro-
phil chemotactic factor during degranulation [33] and lympho-
cytes stimulated by specific antigen release chemotactic factors 
for both macrophages and neutrophils [34]. 
Additional chemotactic factors have been produced in vitro 
by the enzymatic degradation of collagen and immunoglobulins 
[35,36). Though an in vivo role for these substances has not 
been demonstrated, they offer a ubiquitous substrate for che-
motactic factor production. 
Exogenous chemotactins and chemotaxigens have been dem-
onstrated in a variety of micro-organisms [37]. Bacteria produce 
chemotaxins during the rapid phase of culture growth. Some 
organisms possess surface molecules that may activate the 
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alternative complement pathway [38], and chemotaxigens ca-
pable of directly cleaving C5 to C5a [39]. Virus-infected cells 
have been shown to produce chemotactins and activate com-
plement components [40]. 
Of particular interest to dermatologists is recent work show-
ing that yeast, Candida species activate the complement sys-
tem to produce neutrophil chemotactic factors. It is assumed 
that these factors are responsible for the characteristic pustules 
seen in cutaneous candidiasis and the limited invasiveness of 
these organisms in normal hosts [41]. 
It is apparent that there are numerous ways phagocyte che-
motactic factors can be generated. This is not surprising in view 
of the necessity of an efficient chemotactic response for host 
survival. Multiple factors acting in any instance of infection or 
inflammation may be an important "safety" mechanism against 
serious infection when a single chemotactic system fails. 
REGULATION OF THE CHEMOTACTIC RESPONSE 
Regulation of phagocyte chemotaxis is necessary presumably 
to focus and confine cells to sites of inflammation and limit the 
undesirable consequences of unrestrained or inappropriately 
generalized inflammation. Control of the chemotactic response 
may occur at the level of the chemotactic factor .by blocking its 
production or inhibiting its activity, or at the cellular level by 
rendering phagocytes unresponsive to chemotactins. 
At the cellular level, phagocyte deactivation .may play a 
regu latory role. Deactivation occurs follQwing El"xposure ofphag-
ocytes to a chemo-attractant in the absence of a concentration 
gradient. Cells permanently lose their ability to respond to any 
and all chemotactins regardless of the one causing deactivation 
[14]. One consequence of deactivation is the confinement of 
cells to sites of inflammation. Another may be reduction in 
both chemotactic responsiveness and "self-destructive" inflam-
mation in patients with circulating immune complex diseases 
and widespread complement activation. Patients with SLE and 
rheumatoid arthritis often show a diminished phagocyte che-
motactic response [42,43]. 
Cell-directed inhibitors of chemotaxis are produced by in-
flammatory effector cells including neutrophils, monocytes 
[44], and lymphocytes [34]. Two of the best known are the 
le ukocyte migration inhibitory factor and macrophage migra-
tion inhibitory factor. Both are Iymphokines released from 
activated lymphocytes. In addition to the cell-derived factors, 
the serum proteins, alpha 1 antitrypsin and alpha 2 macroglob-
ulin, inhibit chemotaxis at the cellular level [44]. 
Several serum proteins may act directly to inactivate che-
motactic factors. The complement derived chemotactins C3a 
and C5a are inactivated by at least 2 serum proteins, anaphy-
latoxin inactivator and chemotactic factor inactivator. The 
latter protease(s) has activity against kallikrein and plasmino-
gen activator as well as complement-derived factors. P lasmin-
ogen activator and kallikrein are also inhibited by alpha 2 
macroglobulin and kallikrein is inhibited by Cl esterase inhib-
itor [45,46]. 
Regulation of phagocyte chemotaxis is not completely under-
stood but is a very important area. Greater knowledge of 
controlling factors might lead to ways of augmenting or dimin-
ishing the response and decreasing t he chemotactic response 
may prove to be an important means of controlling inflamma-
tion. 
DRUG INHIBITION OF NEUTROPHIL CHEMOTAXIS 
Some patients with inflammatory diseases, Behcet's syn-
drome [47], pyoderma gangrenosum [48], and possibly psoriasis 
[49,50], have unusually brisk neutrophil chemotactic responses 
which has led to speculation that supranormal chemotaxis may 
be related to the lesions in these and perhaps other inflamma-
tory skin diseases. Whether supranormal or normal, pharma-
cologic inhibition of the chemotactic response has obvious 
clinical implications for patients with inflammatory disease. 
Though still of questionable therapeutic value, some work 
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has been done on drug inhibition of phagocyte chemotaxis. 
Drugs which have been reported to be inhibitory are vincristine, 
vinblastine, 6 mercaptopurine, methotrexate, colchicine, gluco-
corticosteroids, chloroquine and the antibiotics griseofulvin, 
erythromycin, tetracycline and clindamycin. In all but a few 
cases, drug inhibition of chemotaxis has been demonstrated 
only in vitro by incubating cells with drugs during or prior to 
measurement of chemotaxis. In practically no cases have cells 
or serum taken from patients receiving the drug been used to 
assess the chemotactic response. 
Colchicine has long been used to treat acute gouty arthritis 
and recently has been reported effective in the treatment of 
Behcet's syndrome [47]. In vitro pharmacologic concentrations 
of colchicine inhibit neutrophil chemotaxis and lysosomal en-
zyme release. Colchicine may inhibit these functions by binding 
to tubulin, and inhibiting microtubular assembly. The vincaal-
kaloids, vincrinstine and vinblastine, are thought to inhibit 
neutrophil chemotaxis by a similar mechanism [3]. 
Griseofulvin is an antitubulin drug but binds to a receptor on 
t.ubulin distinct from colchicine. In vitro griseofulvin inhibits 
neutrophil chemotaxis at concentrations below those reported 
-in patients taking the drug for fungal infection [6]. Griseofulvin 
like colchicine has been reported effective in the treatment of 
gout. 
Other antibiotics, tetracycline HCI, erythromycin base and 
clindamycin HCl will inhibit neutrophil cheinotaxis in vitro and 
at concentrations easily attainable in vivo [52]. Serum from 
patients taking. tetracycline has also been shown to inhibit 
neutrophil chemotaxis [53]. Interestingly, it has been suggested 
that perhaps part of the effectiveness of these agents applied 
topically or systemically in the treatment of acne is due to 
inhibition of phagocyte chemotaxis. 
Several studies have examined the effect of glucocorticoste-
roids on neutrophil chemotaxis in vitro [54-56]. All have re-
ported inhibition but always at suprapharmacologic concentra-
tions. Monocytes appear to be more sensitive to the inhibitory 
effects of steroids but neither monocytes nor neutrophils taken 
from patients on high dose steroids have demonstrated defec-
tive chemotaxis [57,58]. It would appear that inhibition of 
chemotaxis does not offer an explanation for the anti-inflam-
matory effects of glucocorticosteroids. Chloroquine does sup-
press chemotaxis in vitro at pharmacologic concentrations and 
this may be one of its mechanisms for anti-inflammatory activ-
ity [55, 56]. Chloroquine, like steroids, has many other effects 
on the inflammatory response which undoubtedly contribute to 
its therapeutic effectiveness. 
ABNORMAL NEUTROPHIL CHEMOTAXIS 
A number of clinical syndromes and diseases are associated 
with defective phagocyte chemotaxis. Some are of interest to 
dermatologists because affected patients present with severe 
recurrent or intractable skin or subcutaneous infections. Fur-
thermore, many patients have noninfectious cutaneous signs 
which may suggest the possibility of deficient phagocyte che-
motaxis and altered susceptibility to infection. 
Deficiencies of phagocyte chemotaxis can be divided into 
several categories. One group of patients have intrinsic cellular 
defects which prevent the phagocyte from responding normally 
to a chemotactic factor. In another group, the chemotactic 
response may be blocked by cell-directed soluble inhibitors of 
chemotaxis. A third group are deficient in the generation of 
chemotactic factors due to either insufficient production or 
excessive inhibition. In some cases, the defect has not been 
determined. 
INTRINSIC PHAGOCYTE DYSFUNCTION 
Neutrophils and/or monocytes from patients with Chediak-
H igashi syndrome [7] , lazy leukocyte syndrome [59], familial 
chemotactic defect [60] and neutrophil actin dysfunction [10] 
show abnormal chemotaxis presumably due to an intrinsic 
defect in cellular machinery necessary for directed motion. The 
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defect is present in the absence of circulating inhibitors of 
chemotaxis a nd cannot be restored by incubation of cells in 
normal serum. Random motility of cells in these patients may 
or may not be affected. 
The Chediak-Higashi syndrome is characterized by recurrent 
pyogenic infection, granulocytopenia, pigment dilution affecting 
the skin, hair and eyes and giant lysosomal granules in mela-
nocytes and phagocytes. It is suggested that defective assembly 
of microtubules is responsible for the large lysosomal granules 
seen in these cells. Microtubular assembly is activated by cGMP 
and inhibited by cAMP. Although no data is available on 
leukocyte cGMP levels in these patients, cAMP levels are 
greatly elevated. Ascorbic acid which decreases cAMP, im-
proves leukocyte function of CHS leukocytes in vitro. Treat-
ment of CHS patients with ascorbic acid may reduce the 
incidence of infection [20]. If so, this represents one of the few 
treatable defects in phagocyte chemotaxis. 
The lazy leukocyte syndrome is manifested by recurrent low-
grade fever, gingivo-stomatitis and otitis media. These patients 
have defective chemotaxis, random movement and moderately 
severe neutropenia but a normal bone marrow [59]. Defective 
demargination of neutrophils with epinephrine or endotoxin is 
present. A primary defect in neutrophil movement has been 
postulated. 
Two families have been reported with an inherited defect in 
chemotaxis termed familial chemotactic defect. Random move-
ment of neutrophils from patients and family members is nor-
mal, but the neutrophils fail to respond to chemotactic stimuli. 
Cutaneous manifestations of the disease include congenital 
ichthyosis vulgaris and recurrent T. rubrum infection [60]. The 
cause of the defect is unknown. 
A single infant has been described with defective in vitro and 
in vivo chemotaxis and recurrent superficial and deep pyogenic 
infections since birth. Neutrophils from this patient were found 
to have defective actin protein which showed abnormal polym-
erization in vitro. The defect has been called "defective actin 
polymerization" and may represent a specific abnormality of 
microftlament function [10]. 
Acrodermatitis enteropathica (AE) is associated with an ac-
quired intrinsic abnormality of both monocyte and neutrophil 
chemotaxis. The defect is presumably due to zinc deficiency 
since normal motility of phagocytes is restored in patients 
treated with zinc. Zinc added to abnormal AE phagocytes in 
vitro also restores chemotaxis in a dose-dependent fashion. The 
effect of zinc in restoring chemotaxis is not known but some 
observations suggest an effect on the cell membrane [61). 
DISEASES ASSOCIATED WITH CELL-DIRECTED 
INHIBITORS OF CHEMOTAXIS 
In some diseases, chemotaxis of phagocytes may be inhibited 
by soluble serum factors. Included among these conditions are 
the Wiskott-Aldrich syndrome, some collagen vascular diseases 
and allergic reactions associated with hypocomplementemi'a, 
and possibly the hyperirnmunoglobulinemia E (hyper IgE) syn-
drome. 
In recent years, a number of children and adults have been 
described with severe and recurrent bacterial skin infections 
and increased serum immunoglobulin E. levels [62-68). Most 
patients have had defective neutrophil chemotaxis as well. 
Although not a homogeneous patient population, the term 
hyper IgE syndrome has been applied to denote its most 
consistent feature. Patients have recurrent bacterial skin infec-
tions from infancy including nonspecific pyoderma, cellulitis, 
deep and superficial abscesses, erysipelis and impetigo. Staph· 
ylococcus aureus and Streptococcus pyogenes are the most 
common organism isolated but gram-negative bacteria have 
been recovered. Some patients have had recurrent or chronic 
mucocutaneous candidiasis [64] and a few have had chronic T. 
rubrum infection [68). In addition to skin infections, many 
patients have chronic bacterial lymphadenitis, otitis media, 
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dental, retropharyngeal and lymph node abscesses, bronchitis, 
pneumonia, pulmonary empyema and septic arthritis. So called 
"cold abscesses" which lack pain and heat occur typically in 
patients with Job's syndrome, a variant of the hyper IgE 
syndrome. Other features of Job's syndrome in addition to 
increased serum IgE levels and defective neutrophil chemotaxis 
are red hair, atrophic nails and hyperextensible joints [69,70). 
Nearly all patients with hyper IgE syndrome have noninfec-
tious skin manifestations particularly eczema. The eczema is 
often indistinguishable from atopic dermatitis with flexural 
lichenification, pruritus and Denny Morgan lines [71). Neutro-
phil chemotaxis has been observed to approach or return to 
normal as skin infections clear [72). A recent study showed that 
atopic patients with elevated serum IgE but without a previous 
history of severe infection had normal chemotaxis [73). It is not 
known if chemotaxis becomes abnormal in atopies during epi-
sodes of infection. Additional noninfectious skin signs in the 
hyper IgE syndrome include urticaria, congenital ichthyosis 
and incontinentia pigmenti [68,73-75). 
It has been postulated that defective chemotaxis in the hyper 
IgE syndrome is due to circulating histamine acting on the 
neutrophil H2 receptor to increase levels of intracellular cAMP. 
As discussed previously, a number of substances which in-
creased cAMP inhibit chemotaxis. In vitro histamine causes a 
dose-related suppression of neutrophil chemotaxis which can 
be blocked by an H2 blocker such as metiamide. Though 
elevated histamine levels have not been demonstrated in these 
patients, histaminemia has been inferred from the elevated 
serum levels of IgE, the frequent presence of a pruritic skin rash 
and eosinophilia and the appearance of urticaria in some pa-
tients during periods of active infection [19). 
In the Wiskott-Aldrich syndrome (WAS), patients have 
atopic-like eczema, thrombocytopenic purpura, recurrent infec-
tions and a variety of humoral and cellular immunologic dis-
turbances. Many have defective monocyte chemotaxis which 
correlates with high levels of circulating lymphocyte-derived 
chemotactic factor. It is thought that elevated levels of this 
Iymphokine inactivate circulating monocytes. Evidence for in-
activation comes from the observation that normal monocytes 
incubated in WAS serum develop defective chemotaxis [76). In 
SLE, rheumatoid arthritis and other immune complex diseases 
impaired phagocyte chemotaxis has been reported [42,43], and 
may explain in part the increased incidence of infections seen 
in these patients. There are at least 2 possible mechanisms for 
abnormal phagocyte chemotaxis in immune complex diseases. 
One is deactivation of cells by circulating chemotactic factors 
which could be released by the interaction of complement with 
immune complexes. Exposure of cells to C3a or C5a renders 
neutrophils unresponsive to further chemotactic stimulation 
[14]: A second mechanism may be a refractory state induced in 
neutrophils which have phagocytized immune complexes. Cells 
which have been incubated with rheumatoid serum, rheumatoid 
complexes purified from serum or iron dextran particles ex-
hibited impaired chemotaxis [43). Similar mechanisms may 
explain the defective neutrophil chemotaxis observed in pa-
tients with dl'Ug reactions associated with severe hypocomple-
mentemia [77]. 
ABNORMAL GENERATION AND INACTIVATION OF 
CHEMOTACTIC FACTORS 
A delay in the generation of sufficient chemotactic factor 
activity can result in a faulty inflammatory response and in-
creased susceptibility to infection. Clinically, these situations 
may arise when chemotactic factors such as these derived from 
complement are absent or severely depressed or when chemo-
tactic factor inhibitory activity is excessive. 
The best studied examples of deficient chemotactic factor 
production are the relatively rare syndromes associated with 
inherited or acquired complement deficiency. These include 
Cl r, C2, C3, and C5 deficiency and Leiner's disease associated 
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with C5 dysfunction. Obviously since complement components 
play m a ny roles in defe nse against infection, faulty chemotactic 
factor generation is but one cause of abnormal inflammatory 
responses in these patients. 
Patients with a homozygous deficie ncy of Clr or C2 have 
delayed production of ch e motactic factors in sera activated by 
the classical complem ent pathway, but normal production when 
the alternative pathway is activated. It has bee n suggested that 
s u c h a d elay in the generat ion of chemotactic factor may be 
responsible for the moderate increase in pyogenic infection seen 
in these patients [78]. 
As expected, more frequent and severe infections may be 
seen in patients with C3 and C5 deficiency since both alternative 
and classical pa thways of activation are a ffected . Patients with 
C5 deficiency al'e unusually susceptible to infection supporting 
t h e view that C5 is an important ch emotactic factor in host 
defense [79-81]' 
Leiner's syndJ'ome is associated with C5 dysfunction. Though 
total he molytic complement levels are normal in these patients, 
C5-mediated phagocytosis of yeast particles and generation of 
C5a ch emotactic factor is abnormal [81]. 
Patients with C5 d eficiency and C5 dysfunction have on 
occasion benefited from the infusion of fresh normal human 
plasma a nd r e present additional examples of therapy for defec-
t ive chemotaxis. 
A larger group of patie nts with a variety of illnesses including 
sarcoidosis, Hodgkins disease, hepatic cirrhosis and nonspecific 
acute illnesses associated with leukocytosis h ave had elevated 
serum levels of chemotactic factors inactivator activity [82,83]. 
Serum from these patients has demonstrated supranormal sup-
pression of both complement and noncomplement derived che-
motactic factors. 
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